Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803616 | 0.88 | ESR1 (0.44) | ESR1SYKAPPEGFRKIF11 | |
| SCHEMBL22803779 | 0.84 | ESR1 (0.52) | ESR1SYKAPPEGFRKIF11 | |
| SCHEMBL22803606 | 0.82 | SYK (0.45) | ESR1SYKAPPEGFRCSNK2A1 | |
| SCHEMBL22803617 | 0.82 | SYK (0.42) | ESR1SYKAPPEGFRKIF11 | |
| SCHEMBL22803626 | 0.81 | ESR1 (0.51) | ESR1SYKAPPEGFRKIF11 | |
| SCHEMBL29714372 | 0.81 | ESR1 (0.49) | ESR1SYKEGFRKIF11CSNK2A1 | |
| SCHEMBL22778100 | 0.81 | ESR1 (0.49) | ESR1SYKEGFRKIF11CSNK2A1 | |
| SCHEMBL22803804 | 0.80 | ESR1 (0.54) | ESR1SYKAPPEGFRKIF11 | |
| SCHEMBL22803620 | 0.80 | APP (0.41) | ESR1SYKAPPEGFRCSNK2A1 | |
| SCHEMBL22803609 | 0.79 | SYK (0.46) | ESR1SYKAPPEGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | ESR1 3661/4885SYK 1069/4885APP 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.